Q linea

Q linea Interest Coverage

The Interest Coverage Ratio of Q linea (QLINEA.ST) as of Nov 4, 2026 is -30.48. In the previous year, Interest Coverage Ratio was -65.01 — a change of -53.12% (higher).

Interest Coverage

-30.48

YoY

-53.12%

Last updated:

Interest Coverage Ratio of Q linea is 2025 -30.48 . Interest Coverage Ratio of Q linea was 2024 -65.01 . It decreases by -53.12% higher compared to the previous year.

The Q linea Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-128.91 SEK
Jan 1, 2019
-101.71 SEK
Jan 1, 2020
-76.74 SEK
Jan 1, 2021
-695.09 SEK
Jan 1, 2022
-38.04 SEK
Jan 1, 2023
-310.35 SEK
Jan 1, 2024
-65.01 SEK
Jan 1, 2025
-30.48 SEK
The Q linea Interest Coverage history
YEARInterest CoverageYoY
-30.48-53.12%
-65.01-79.05%
-310.35+715.84%
-38.04-94.53%
-695.09+805.79%
-76.74-24.55%
-101.71-21.10%
-128.91-98.10%
-6,787.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Interest Coverage Ratio of Q linea is -30.48 in 2025.

Interest Coverage Ratio of Q linea changed from -65.01 to -30.48, representing a -53.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Q linea since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Q linea with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Q linea

All Key Metrics — Q linea